Ampersand Capital Partners-backed Julius Clinical completed the merger with Peachtree BioResearch Solutions.

Ampersand Capital Partners-backed Julius Clinical, a Contract Research Organization, completed the merger with Peachtree BioResearch Solutions, a specialised in central nervous system Contract Research Organization. Financial terms were not disclosed. "We are thrilled to merge with Peachtree BioResearch Solutions. This marks a significant step forward in expanding our presence and deepening our capabilities across North America and Europe. This natural evolution of our long-term successful relationship allows us to leverage our aligned strengths to become a more versatile and capable partner for our clients," Martijn Wallert, Julius Clinical Chief Executive Officer.